Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug, amycretin.
In a Phase 1b/2a trial, amycretin led to up to 22% weight loss over 36 weeks, showing a safety profile similar to Novo's semaglutide and Eli Lilly's (NYSE:LLY) tirzepatide. The 125-subject study evaluated the drug's safety, tolerability, and effectiveness in overweight and obese individuals. Patients taking 1.25 mg for 20 weeks lost 9.7% of their weight, those on 5 mg for 28 weeks lost 16.2%, and the 20 mg group at 36 weeks saw 22% weight loss.
Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, showing similar weight-loss effects. Martin Lange, Novo's head of drug development, said the results reinforce amycretin's potential as a next-generation obesity treatment.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。